Clinical trials: Cephalalgia, open to volunteers
Migraine, With or Without Aura
Long-term Safety of BR005-036C Tablets in the Acute Treatment of Migraine in Adults
The purpose of this study is to evaluate the long-term safety of BR005-036C tablets in the acute treatment of migraines
- Trial name
- NCT07835152
- Testing
- BR005-036C
- Where
- 81 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Brise Pharmaceuticals Co., Ltd.
Chronic Migraine
Acceptance and Commitment Therapy to Improve Disability in Chronic Migraine
The goal of this clinical trial is to learn if the behavioral treatment called Acceptance and Commitment Therapy (ACT) works to improve disability in adults with chronic migraine.
- Trial name
- NCT06795867
- Testing
- acceptance and commitment therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Brigham and Women's Hospital
Migraine, With or Without Aura
Efficacy and Safety of BR005-036C Tablets for the Acute Treatment of Migraine in Adults
The purpose of this study is to compare the efficacy and safety of BR005-036C versus placebo in subjects with Acute Migraines
- Trial name
- NCT07792681
- Testing
- BR005-036C
- Where
- 83 sites in China
- Volunteers
- 2,079 people
- Sponsor
- Brise Pharmaceuticals Co., Ltd.
Headache (Migraine)
Prevalence and Determinants of Migraine Among Headache Patients
Migraine is a prevalent and disabling neurological condition that often coexists with other health issues, such as hypertension and impaired physical, mental, and social functioning.
- Trial name
- NCT07038499
- Where
- China
- Volunteers
- 158 people
- Sponsor
- Universiti Tunku Abdul Rahman
Trigeminal Autonomic Cephalalgias, Cluster Headache
Italian Trigeminal Autonomic Cephalalgias Assessment Study
ITACA is a prospective, multicenter, observational longitudinal cohort study conducted in routine clinical practice at six Italian headache centers.
- Conditions
- Trigeminal Autonomic Cephalalgias, Cluster Headache, Paroxysmal Hemicrania, SUNCT
- Trial name
- ITACA (NCT07812740)
- Where
- Italy
- Volunteers
- 800 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Migraine
Tryptophan as a Modulating Factor in the Antimigraine Efficacy of Triptans
Migraine is a leading cause of disability, and while triptans are commonly used to treat migraine attacks, over 20% of patients don't respond well to them.
- Trial name
- TRP-Triptans (NCT07177885)
- Testing
- Blood collection
- Where
- France
- Volunteers
- 144 people
- Sponsor
- University Hospital, Clermont-Ferrand